Bristol-Myers Squibb saxagliptin

USAN Saxagliptin Trade Name Onglyza Bristol-Myers Squibb Co. Launched 2009... 

The DPP-4 enzyme inactivates incretin hormones such as GLP-1. Some diabetes drugs work by inhibiting DPP-4 and therefore slow the inactivation of incretin hormones. SitagUptan (the phosphate salt is marketed as Januvia , Merck) and saxagliptin (Onglyza , Bristol-Myers Squibb) are examples of DPP-4 inhibitors. 

Saxagliptin 32 [187-189] (Figure 11.31), a DPP-IV inhibitor developed by Bristol-Myers Squibb, requires (S)-N-boc-3-hydroxyadamantylglycine 103 as... 

Dipeptidyl peptidase 4 (DPP-4) is a ubiquitous proline-specific serine protease responsible for the rapid inactivation of glucagon-like peptide 1 (GLP-1). To alleviate the inactivation of GLP-1, inhibitors of DPP-4 are being evaluated for their ability to provide improved control of blood glucose for diabetics and treatment for type 2 diabetes [21]. Saxagliptin 1 [22-24] (Figure 4.1), a DPP-4 inhibitor developed by Bristol-Myers Squibb (BMS), requires (S)-N-boc-3-hydroxyadamantylglycine 2 as a key intermediate. 

---